Follow
Graham Wheeler
Title
Cited by
Cited by
Year
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16, 1-15, 2018
5602018
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
AL Ahern, GM Wheeler, P Aveyard, EJ Boyland, JCG Halford, AP Mander, ...
The Lancet 389 (10085), 2214-2225, 2017
2182017
How to design a dose-finding study using the continual reassessment method
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19, 1-15, 2019
902019
Adaptive designs for dual-agent phase I dose-escalation studies
JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell
Nature Reviews Clinical Oncology 10 (5), 277-288, 2013
772013
Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia
C Roddie, J Dias, MA O'Reilly, M Abbasian, A Cadinanos-Garai, ...
Journal of Clinical Oncology 39 (30), 3352, 2021
732021
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
T Burnett, P Mozgunov, P Pallmann, SS Villar, GM Wheeler, T Jaki
BMC medicine 18, 1-21, 2020
602020
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, G Wheeler, CN Sternberg, R Jones, ...
Annals of Oncology 32 (6), 726-735, 2021
302021
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
V Homer, C Yap, S Bond, J Holmes, D Stocken, K Walker, EJ Robinson, ...
bmj 376, 2022
212022
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
GM Wheeler, MJ Sweeting, AP Mander
Statistics in Medicine 36 (16), 2499-2513, 2017
212017
A review of available software for adaptive clinical trial design
MJ Grayling, GM Wheeler
Clinical Trials 17 (3), 323-331, 2020
182020
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
G Wheeler, M Sweeting, A Mander
PLoS ONE 11 (7), e0159026, 2016
172016
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
G Wheeler
Statistical Papers, 1-11, 2016
112016
Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of …
AL Ahern, P Breeze, F Fusco, SJ Sharp, N Islam, GM Wheeler, AJ Hill, ...
The Lancet Public Health 7 (10), e866-e875, 2022
102022
Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ...
Clinical Cancer Research 26 (18), 4748-4755, 2020
102020
Visualising harms in publications of randomised controlled trials: consensus and recommendations
R Phillips, S Cro, G Wheeler, S Bond, TP Morris, S Creanor, C Hewitt, ...
bmj 377, 2022
72022
ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in relapsed/refractory B-cell acute lymphoblastic Leukaemia and other B-cell malignancies
C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias, AC Garai, ...
Blood 136, 3-4, 2020
72020
Designing and evaluating dose-escalation studies made easy: the MoDEsT web app
P Pallmann, F Wan, AP Mander, GM Wheeler, C Yap, S Clive, ...
Clinical Trials 17 (2), 147-156, 2020
72020
AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
C Roddie, MA O'Reilly, MAV Marzolini, L Wood, JDA Pinto, M Abbasian, ...
Blood 134, 226, 2019
72019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data
GM Wheeler, MJ Sweeting, AP Mander
Journal of the Royal Statistical Society Series C: Applied Statistics 68 (2 …, 2019
72019
Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
GM Wheeler, MJ Sweeting, AP Mander, SM Lee, YKK Cheung
Statistics in medicine 36 (2), 225-241, 2017
72017
The system can't perform the operation now. Try again later.
Articles 1–20